Abstract
Abuse of psychostimulants presents a significant health and social problem worldwide. Traditionally, the dopaminergic system has received much attention for its role in the development and manifestation of addictive behavior. The identification of the close interaction between the dopaminergic and glutamatergic pathway and by extension the nitric oxide (NO) signaling pathway (the nitrergic system) have provided a broader scope on the mechanisms underlying the development of addictive behavior following exposure to cocaine and methamphetamine. NO signaling is associated with the acquisition and maintenance of several behavioral phenotypes induced by cocaine and methamphetamine (METH), as well as in METH-induced dopaminergic depletion. Because it appears that NO signaling influences response to reward, memory formation, and free radical-induced neurotoxicity, pharmacotherapies targeting NO signaling pathway may prove beneficial in the treatment of psychostimulants abuse.
Keywords: Adolescence, adulthood, cocaine, conditioned place preference, dopamine, methamphetamine, neurotoxicity, nitric oxide (NO), psychostimulant, sensitization.
Current Pharmaceutical Design
Title:Nitric Oxide (NO) Signaling as a Potential Therapeutic Modality Against Psychostimulants
Volume: 19 Issue: 40
Author(s): Shervin Liddie, Mara A. Balda and Yossef Itzhak
Affiliation:
Keywords: Adolescence, adulthood, cocaine, conditioned place preference, dopamine, methamphetamine, neurotoxicity, nitric oxide (NO), psychostimulant, sensitization.
Abstract: Abuse of psychostimulants presents a significant health and social problem worldwide. Traditionally, the dopaminergic system has received much attention for its role in the development and manifestation of addictive behavior. The identification of the close interaction between the dopaminergic and glutamatergic pathway and by extension the nitric oxide (NO) signaling pathway (the nitrergic system) have provided a broader scope on the mechanisms underlying the development of addictive behavior following exposure to cocaine and methamphetamine. NO signaling is associated with the acquisition and maintenance of several behavioral phenotypes induced by cocaine and methamphetamine (METH), as well as in METH-induced dopaminergic depletion. Because it appears that NO signaling influences response to reward, memory formation, and free radical-induced neurotoxicity, pharmacotherapies targeting NO signaling pathway may prove beneficial in the treatment of psychostimulants abuse.
Export Options
About this article
Cite this article as:
Liddie Shervin, Balda A. Mara and Itzhak Yossef, Nitric Oxide (NO) Signaling as a Potential Therapeutic Modality Against Psychostimulants, Current Pharmaceutical Design 2013; 19 (40) . https://dx.doi.org/10.2174/138161281940131209144527
DOI https://dx.doi.org/10.2174/138161281940131209144527 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research What Can Neuroscience Tell Us About the Potential of Psychedelics in Healthcare? How the Neurophenomenology of Psychedelics Research Could Help us to Flourish Throughout Our Lives, as Well as to Enhance Our Dying
Current Drug Abuse Reviews Drug Evolution: p-Aminobenzoic Acid as a Building Block
Current Medicinal Chemistry Alginate Based Nanocarriers for Drug Delivery Applications
Current Pharmaceutical Design Classical Neurotransmitters and Neuropeptides Involved in Major Depression in a Multi-neurotransmitter System: A Focus on Antidepressant Drugs
Current Medicinal Chemistry Molecular Manipulation Targeting Regulation of Dopaminergic Differentiation and Proliferation of Neural Stem Cells or Pluripotent Stem Cells
CNS & Neurological Disorders - Drug Targets Human Brain Nicotinic Receptors, their Distribution and Participation in Neuropsychiatric Disorders
Current Drug Targets - CNS & Neurological Disorders Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) 5-HT2 Receptors
Current Drug Targets - CNS & Neurological Disorders An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds
Current Medicinal Chemistry Modulation of Apoptosis in Acute Ischemic Stroke as Treatment Challenges
Current Immunology Reviews (Discontinued) Food Fortification with Omega-3 Fatty Acids; Microencapsulation as an Addition Method
Current Nutrition & Food Science Human Chorionic Gonadotropin: A Model Molecule For Oligopeptide-Based Drug Discovery
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Editorial: View of Excellent ROAD from the CAR
Current Alzheimer Research Nicotine Effects, Body Weight Concerns and Smoking: A Literature Review
Current Pharmaceutical Design Age-Specific Impairment of Morris Water Maze Performance Following Neonatal Exposure to Magnetic Resonance Image in Rats
Current Neurovascular Research Histone Deacetylase Inhibitors in Psoriasis Therapy
Current Drug Targets - Inflammation & Allergy